Progenics and Wyeth Announce FDA Has Approved RELISTOR: First Drug for Opioid-Induced Constipation to Launch in United States - Maternity.com Forums. Your Online Community for Parents and Expecting Parents.

04-30-2008, 04:55 PM

WomensIssues WomensIssues is offline

Maternity.com VIP

Senior Citizen

Join Date: May 2006

Posts: 28,278

Rep Power: 0

WomensIssues is an unknown quantity at this point

Progenics and Wyeth Announce FDA Has Approved RELISTOR: First Drug for Opioid-Induced Constipation to Launch in United States

Progenics and Wyeth Announce FDA Has Approved RELISTOR: First Drug for Opioid-Induced Constipation to Launch in United States

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that the U.S. Food and Drug Administration (FDA) has approved RELISTOR(TM) (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. In clinical studies, RELISTOR significantly decreased the constipating effects of opioids without interfering with pain relief. Wyeth expects to make RELISTOR available in the United States in early June. (PRWeb Apr 24, 2008)

Read the full story at [Please register to see this link Register]

[Please register to see this link Register]